Introduction of unsaturation into the N-n-Alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: Effect on affinity and selectivity

AAPS Journal

Volumn 7, Issue 1, 2005, Pages

  Sumithran, Sangeetha P ^a   Crooks, Peter A ^a   Xu, Rui ^a,b   Zhu, Jun ^a   Deaciuc, Agripina G ^a   Wilkins, Lincoln H ^a,c   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

^b ARRAY BIOPHARMA INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dopamine release; Dopamine transporter; Drug discovery; Nicotine; Nicotinic receptor antagonist

Indexed keywords

ALKYL GROUP; DOPAMINE; HISTONE H3; METHYLLYCACONITINE; N N DECYLNICOTINIUM IODIDE; N N OCTYLNICOTINIUM IODIDE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RUBIDIUM 86; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BINDING AFFINITY; BINDING ASSAY; CHEMICAL BOND; CIS ISOMER; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ION TRANSPORT; MALE; NONHUMAN; RAT; REVIEW; STATISTICAL ANALYSIS; STRUCTURE ANALYSIS; TRANS ISOMER;

ACONITINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ELECTRIC STIMULATION; HUMANS; MALE; MOLECULAR STRUCTURE; NICOTINE; NICOTINIC ANTAGONISTS; NOMIFENSINE; PROTEIN BINDING; PROTEIN SUBUNITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; REWARD; RUBIDIUM; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 27644501400     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070119     Document Type: Review

References (107)

1. Clarke PB. Nicotine and smoking: a perspective from animal studies. Psychopharmacology (Berl). 1987;92:135-143.
2. Pomerleau CS, Pomerleau OF. Euphoriant effects of nicotine in smokers. Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl). 1992; 108:460-465.
3. Balfour DJ. The neurobiology of tobacco dependence: a commentary. Respiration. 2002;69:7-11.
4. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171-191.
5. Corrigall WA, Franklin KBJ, Coen YM, Clarke PBS. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl). 1992;107:285-289.
6. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl). 1995;117:2-10.
7. Pontieri F, Tanda G, Orgi F, DiChiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382:255-257.
8. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999;24:521-527.
9. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393:295-314.
10. Wise RA. Addiction becomes a brain disease. Neuron. 2000;26:27-33.
11. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469-492.
12. Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol. 1998;12:37-67.
13. Koob GF. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann N Y Acad Sci. 1999;877:445-460.
14. Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47:227-241.
15. Fibiger HC, Phillips AG. Role of catecholamine transmitters in brain reward systems. In: Engel J, Oreland L, eds. Brain Reward Systems and Abuse. New York, NY: Raven Press; 1987:61-74.
16. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol. 2002;53:606-617.
17. Mathieu-Kia AM, Kellog SH, Butelman ER, Kreek MJ. Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl). 2002;162:102-118.
18. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28:309-369.
19. Shima K, Tanji J. Role for cingulate motor area cells in voluntary movement selection based on reward. Science. 1998;282:1335-1338.
20. Rose JE, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res. 2004;6:523-532.
21. Brody AL, Mandelkern MA, Lee G, et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res. 2004;130:269-281.
22. Martin-Soelch C, Leenders YL, Chevalley AF, et al. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev. 2001;36:139-149.
23. Stein EA, Pankiewicz J, Harsch HH, et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry. 1998;155:1009-1015.
24. 11C]raclopride. Synapse. 2004;54:65-71.
25. Parker MJ, Beck A, Luetje CW. Neuronal nicotinic receptor β2 and β4 subunits confer large differences in agonist binding affinity. Mol Pharmacol. 1998;54:1132-1139.
26. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 1995;57:521-546.
27. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20:92-98.
28. Luetje CW. Getting past the asterisk: the subunit composition of presynaptic nicotinic receptors that modulate striatal dopamine release. Mol Pharmacol. 2004;65:1333-1335.
29. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74:363-396.
30. Irvine JE, Hendericks PS, Brandon TH. The increasing recalcitrance of smokers in clinical trials II: pharmacotherapy trials. Nicotine Tob Res. 2003;5:27-35.
31. Hurt RD, Krook JE, Croghan IT, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003;21:914-920.
32. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci. 2004;25:42-48.
33. Wileyto P, Patterson F, Niaura R, et al. Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res. 2004;6:357-366.
34. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol. 1984;104:277-286.
35. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology. 1989;2:273-279.
36. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
37. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology. 2002;42:181-190.
38. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004;66:675-682.
39. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999;288:88-92.
40. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321-327.
41. Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther. 2002;302:1113-1122.
42. Gumilar F, Arias HR, Spitzmaul G, Bouzat C. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology. 2003;45:964-976.
43. 3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem. 1992;59:848-856.
44. 3H]-dopamine. J Pharmacol Exp Ther. 1997;283:778-787.
45. 3H]dopamine overflow from super-fused rat striatal slices. J Pharmacol Exp Ther. 2002;301:1088-1096.
46. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther. 1994;56:86-99.
47. Rose JE, Westman EC, Behm FM, Johnson MP, Goldberg JS. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol Biochem Behav. 1999;62:165-172.
48. Anand R, Conroy WG, Schoepfer R, Whiting P, Lindstrom J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem. 1991;266:11192-11198.
49. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature. 1991;350:235-238.
50. Boorman JP, Groot-Kormelink PJ, Sivilotti LG. Stoichiometry of human recombinant neuronal nicotinic receptors containing the β3 subunit expressed in Xenopus oocytes. J Physiol. 2000;529:565-577.
51. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem. 2002;82:468-481.
52. Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol. 1995;40:155-172.
53. Lindstrom J. Neuronal nicotinic acetylcholine receptors. In: Narahashi T, ed. Ion Channels, vol. 4, New York, NY: Plenum Press;1996:377-450.
54. Lindstrom J. The structures of neuronal nicotinic receptors. In: Clementi F, Fornasari D, Gotti C. eds. Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors, vol. 144. Berlin, Germany: Springer; 2000:101-162.
55. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. α 10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA. 2001;98:3501-3506.
56. Luetje CW, Patrick J. Both alpha and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci. 1991;11:837-845.
57. Harvey SC, Luetje CW. Determinants of competitive antagonist sensitivity on neuronal nicotinic receptorβ subunits. J Neurosci. 1996;16:3798-3806.
58. Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A. Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature. 1996,380:347-351.
59. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1997;280:346-356.
60. Kuryatov A, Olale F, Cooper J, Choi J, Lindstrom J. Human α6 subtypes: subunit composition, assembly and pharmacological responses. Neuropharmacology. 2000;39:2570-2590.
61. Papke RL. The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog Neurobiol. 1993;41:509-531.
62. Sgard F, Charpantier E, Bertrand S, et al. A novel human nicotinic receptor subunit, α10 that confers functionality to the α9-subunit. Mol Pharmacol. 2002;61:150-159.
63. Whiting P, Schoepfer R, Lindstrom J, Priestley T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol Pharmacol. 1991;40:463-472.
64. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41:31-37.
65. Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. Nicotine-induced increase in the neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol. 1994;46:523-530.
66. 3H]methyllycaconitine: a new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology. 1999;38:679-690.
67. Wada E, Wada K, Boulter J, et al. Distribution of alpha 2, alpha 3, alpha 4 and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J Comp Neurol. 1989;284:314-335.
68. Deneris ES, Boulter J, Swanson LW, Patrick J, Heinemann S. β3: a new member of nicotinic acetylcholine receptor gene family is expressed in brain. J Biol Chem, 1989;264:6268-6272.
69. Klink R, d'Exaerde AA, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci. 2001;21:1452-1463.
70. Azam L, Winzer-Serjhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol. 2002;444:260-274.
71. Lukas RJ, Changeux JP, Le Novere N, et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51:397-401.
72. Kulak JM, Nguyen TA, Olivera BM, McIntosh JM. Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci. 1997;17:5263-5270.
73. 3H]dopamine release from rat striatal synaptosomes and slices. J Neurochem. 1998;70:1069-1076.
74. Grady SR, Meinerz NM, Cao J, et al. Nicotine agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem. 2001;76:258-268.
75. 3H]dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther. 2003;306:1011-1020.
76. Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett. 2004;14:1863-1867.
77. Luetje CW, Wada K, Rogers S, et al. Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit combinations. J Neurochem. 1990;55:632-640.
78. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. J Biol Chem. 1996;271:7522-7528.
79. Harvey SC, McIntosh JM, Cartier GE, Maddox FN, Luetje CW. Determinants of specificity for α-conotoxin MII on α3β2 neuronal nicotinic receptors. Mol Pharmacol. 1997;51:336-342.
80. Schulz DW, Zigmond RE. Neuronal bungarotoxin blocks the nicotinic stimulation of endogenous dopamine release from rat striatum. Neurosci Lett. 1989;98:310-316.
81. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173-177.
82. Whiteaker P, Marks MJ, Grady SR, et al. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. Eur J Pharmacol. 2000;393:123-135.
83. 3H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther. 2002;301:651-660.
84. Champtiaux N, Han ZY, Bessis A, et al. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci. 2002;22:1208-1217.
85. Champtiaux N, Gotti C, Cordero-Erausquin M, et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci. 2003;23:7820-7829.
86. Whiteaker P, Peterson CG, Xu W, et al. The role of the α3 subunit in neuronal nicotinic biding populations. J Neurosci. 2002;22:2522-2529.
87. McIntosh JM, Azam L, Staheli S, et al. Analogs of α-conotoxin MII are selective for α6-containing nicotinic acetylcholine receptors. Mol Pharmacol. 2004;65:944-952.
88. Le Novere N, Zoli M, Changeux JP. Neuronal nicotine receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci. 1996;8:2428-2439.
89. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci. 2002;22:8785-8789.
90. Cui C, Booker TK, Allen RS, et al. The β3 nicotinic receptor subunit: a component of α-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci. 2003;23:11045-11053.
91. Goldner FM, Dineley KT, Patrick JW. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit ↑ to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport. 1997;8:2739-2742.
92. Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport. 1998;9:3097-3101.
93. Salminen O, Murphy KL, McIntosh JM, et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol. 2004;65:1526-1535.
94. Zwart R, Vijverberg HP. Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopia laevis oocytes. Mol Pharmacol. 1998;54:1124-1131.
95. Lopez-Hernandez GY, Sanchez-Padilla J, Ortiz-Acevedo A, et al. Nicotine-induced upregulation and desensitization of α4β2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem. 2004;279:38007-38015.
96. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometrics of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol. 2003;63:332-341.
97. 3H]dopamine release by pyridino N-substituted nicotine analogues: a new class of nicotinic antagonist. Drug Dev Res. 1995;36:91-102.
98. Dwoskin LP, Xu R, Ayers JT, Crooks PA. Recent developments in neuronal nicotinic acetylcholine receptor antagonists. Exp Opin Ther Pat. 2000;10:1561-1581.
99. Dwoskin LP, Crooks PA. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther. 2001;298:395-402.
100. Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-Alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with α4β2* and α7* neuronal nicotinic receptors. J Pharmacol Exp Ther. 2003;304:400-410.
101. Crooks PA, Xu R, Sumithran SP, Deaciuc AG, Dwoskin LP. NONI and NDNI analogs: structural modification of the N-n-alkyl moiety and the effect on neuronal nicotinic receptor activity. Bioorg Med Chem. 2005.
102. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
103. + efflux from thalamic synaptosomes. Neuropharmacology. 2000;39:2654-2662.
104. Zhu J, Crooks PA, Ayers JT, Sumithran SP, Dwoskin LP. N-n-Alkylnicotinium and N-n- alkylpyridinium analogs inhibit the dopamine transporter: Selectivity as nicotinic receptor antagonists. Drug Dev Res. 2003;60:270-284.
105. 50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
106. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotinic enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269:1692-1696.
107. 3H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol. 2000;58:312-318.